C Balaña1, A Estival2, I Teruel2, M Hardy-Werbin3, J Sepulveda4, E Pineda5, M Martinez-García6, O Gallego7, R Luque8, M Gil-Gil9, C Mesia9, S Del Barco10, A Herrero11, A Berrocal12, P Perez-Segura13, R De Las Penas14, J Marruecos15, R Fuentes15, G Reynes16, J M Velarde17, A Cardona18,19,20, E Verger21, C Panciroli17, S Villà22. 1. Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain. cbalana@iconcologia.net. 2. Medical Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Ctra Canyet, s/n, 08916, Badalona (Barcelona), Spain. 3. Cancer Research Programm, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 4. Medical Oncology Service, Hospital Universitario, 12 de Octubre, Madrid, Spain. 5. Medical Oncology Service, Hospital Clinic Provincial, Barcelona, Spain. 6. Medical Oncology Service, Hospital del Mar, Barcelona, Spain. 7. Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain. 8. Medical Oncology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain. 9. Medical Oncology Service, Institut Català d'Oncologia-IDIBELL, Hospitalet de Llobregat, Spain. 10. Medical Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain. 11. Medical Oncology Service, Hospital Miguel Servet, Saragossa, Spain. 12. Medical Oncology Service, Hospital General Universitario de Valencia, Valencia, Spain. 13. Medical Oncology Service, Hospital Universitario Clínico San Carlos, Madrid, Spain. 14. Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain. 15. Radiation Oncology Service, Institut Català d'Oncologia, Hospital Josep Trueta, Girona, Spain. 16. Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain. 17. Institut Investigació Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Badalona, Spain. 18. Clinical and Translational Oncology Group, Clínica del Country, Bogotá, Colombia. 19. Foundation for Clinical and Applied Cancer Research, FICMAC, Bogotá, Colombia. 20. Biology Systems Department, Universidad el Bosque, Bogotá, Colombia. 21. Radiation Oncology Service, Hospital Clinic Provincial, Barcelona, Spain. 22. Radiation Oncology Service, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Abstract
PURPOSE: We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients. PATIENTS AND METHODS: We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy. RESULTS: OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor. CONCLUSION: In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
PURPOSE: We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastomapatients. PATIENTS AND METHODS: We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy. RESULTS:OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor. CONCLUSION: In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
Entities:
Keywords:
Glioblastoma; MGMT; Neoadjuvant; Neoadjuvant therapy; Overall survival; Prognosis; Radiotherapy delay; Unresected; Waiting time to radiotherapy
Authors: M R Fetell; S A Grossman; J D Fisher; B Erlanger; E Rowinsky; J Stockel; S Piantadosi Journal: J Clin Oncol Date: 1997-09 Impact factor: 44.544
Authors: Laia Capdevila; Sara Cros; Jose-Luis Ramirez; Carolina Sanz; Cristina Carrato; Margarita Romeo; Olatz Etxaniz; Cristina Hostalot; Ana Massuet; Jose Luis Cuadra; Salvador Villà; Carmen Balañà Journal: J Neurooncol Date: 2014-01-07 Impact factor: 4.130
Authors: Patrick Y Wen; Susan M Chang; Martin J Van den Bent; Michael A Vogelbaum; David R Macdonald; Eudocia Q Lee Journal: J Clin Oncol Date: 2017-06-22 Impact factor: 44.544
Authors: Chirag G Patil; Anthony Yi; Adam Elramsisy; Jethro Hu; Debraj Mukherjee; Dwain K Irvin; John S Yu; Serguei I Bannykh; Keith L Black; Miriam Nuño Journal: J Neurosurg Date: 2012-08-24 Impact factor: 5.115
Authors: Francesc Graus; Jordi Bruna; Javier Pardo; Domingo Escudero; Dolores Vilas; Inés Barceló; Marta Brell; Carmen Pascual; José A Crespo; Elena Erro; Juan C García-Romero; Jordi Estela; Juan Martino; Almudena García-Castaño; Elena Mata; Manuela Lema; Miguel Gelabert; Rafel Fuentes; Pedro Pérez; Arancha Manzano; Jesús Aguas; Antonio Belenguer; Ana Simón; Iván Henríquez; Mauricio Murcia; Rosa Vivanco; Iñigo Rojas-Marcos; David Muñoz-Carmona; Inmaculada Navas; Pablo de Andrés; Gemma Mas; Miguel Gil; Eugènia Verger Journal: Neuro Oncol Date: 2013-03-03 Impact factor: 12.300
Authors: Carmen Balaña; Jaume Capellades; Estela Pineda; Anna Estival; Josep Puig; Sira Domenech; Eugenia Verger; Teresa Pujol; Maria Martinez-García; Laura Oleaga; JoseMaria Velarde; Carlos Mesia; Rafael Fuentes; Jordi Marruecos; Sonia Del Barco; Salvador Villà; Cristina Carrato; Oscar Gallego; Miguel Gil-Gil; Jordi Craven-Bartle; Francesc Alameda Journal: Cancer Med Date: 2017-11-03 Impact factor: 4.452